EXPRESSION OF CYTOKERATIN CONFERS MULTIPLE-DRUG RESISTANCE

被引:73
作者
BAUMAN, PA
DALTON, WS
ANDERSON, JM
CRESS, AE
机构
[1] UNIV ARIZONA,ARIZONA HLTH SCI CTR,DEPT RADIAT ONCOL,TUCSON,AZ 85724
[2] UNIV ARIZONA,ARIZONA HLTH SCI CTR,DEPT PHARMACOL & TOXICOL,TUCSON,AZ 85724
[3] UNIV ARIZONA,ARIZONA HLTH SCI CTR,DEPT MED,TUCSON,AZ 85724
关键词
MULTIDRUG RESISTANCE; CYTOSKELETON;
D O I
10.1073/pnas.91.12.5311
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The cytokeratin network is an extensive filamentous structure in the cytoplasm whose biological function(s) is unknown. Based upon previous data showing the modification of cytokeratin by mitoxantrone, we investigated the ability of cytokeratin networks to influence the survival response of cells to chemotherapeutic agents. We have compared the survival of mouse L fibroblasts lacking cytokeratins with that of L cells transfected with cytokeratins 8 and 18 in the presence of chemotherapeutic drugs. The expression of cytokeratins 8 and 18 conferred a multiple drug resistance phenotype on cells exposed to mitoxantrone, doxorubicin, methotrexate, melphalan, Colcemid, and vincristine. The degree of drug resistance was 5-454 times that of parental cells, depending upon the agent used. Drug resistance could not be attributed to altered growth characteristics, altered drug accumulation, or an altered drug efflux in the transfected cells. Cytokeratin does not confer resistance to ionizing radiation, which damages DNA independently of intracellular transport mechanisms. These data suggest a role for cytokeratin networks in conferring a drug resistance phenotype.
引用
收藏
页码:5311 / 5314
页数:4
相关论文
共 19 条
[1]  
BERLIN V, 1981, J BIOL CHEM, V256, P4747
[2]   THE NUCLEAR MATRIX - 3-DIMENSIONAL ARCHITECTURE AND PROTEIN-COMPOSITION [J].
CAPCO, DG ;
WAN, KM ;
PENMAN, S .
CELL, 1982, 29 (03) :847-858
[3]  
CARMICHAEL J, 1987, CANCER RES, V47, P936
[4]  
CHAN R, 1986, CANCER RES, V46, P6353
[5]   MODIFICATION OF KERATIN BY THE CHEMOTHERAPEUTIC DRUG MITOXANTRONE [J].
CRESS, AE ;
ROBERTS, RA ;
BOWDEN, GT ;
DALTON, WS .
BIOCHEMICAL PHARMACOLOGY, 1988, 37 (15) :3043-3046
[6]  
DENNY WA, 1989, ANTI-CANCER DRUG DES, V4, P241
[7]   THE CDNA SEQUENCE OF A TYPE-II CYTOSKELETAL KERATIN REVEALS CONSTANT AND VARIABLE STRUCTURAL DOMAINS AMONG KERATINS [J].
HANUKOGLU, I ;
FUCHS, E .
CELL, 1983, 33 (03) :915-924
[8]   SURFACE GLYCOPROTEIN MODULATING DRUG PERMEABILITY IN CHINESE-HAMSTER OVARY CELL MUTANTS [J].
JULIANO, RL ;
LING, V .
BIOCHIMICA ET BIOPHYSICA ACTA, 1976, 455 (01) :152-162
[9]   FUNCTIONS OF INTERMEDIATE FILAMENTS [J].
KLYMKOWSKY, MW ;
BACHANT, JB ;
DOMINGO, A .
CELL MOTILITY AND THE CYTOSKELETON, 1989, 14 (03) :309-331
[10]   DRUG-INDUCED ALTERATIONS OF CYTOKERATIN ORGANIZATION IN CULTURED EPITHELIAL-CELLS [J].
KNAPP, LW ;
OGUIN, WM ;
SAWYER, RH .
SCIENCE, 1983, 219 (4584) :501-503